The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of Medicine
  • Home
  • Admissions
  • About
    • Strategic Plan
    • Vision & Values
    • Land Acknowledgement
    • Indigenous Health
    • Leadership
    • Academic & Research Units
    • Campuses
    • Facts & Figures
    • Careers
    • Contact
  • News
    • Feature Stories
    • Pathways Magazine
    • The Next Big Question
  • Education
    • Programs
    • Faculty Development
    • Health Education Scholarship
    • Continuing Professional Development
  • Research
    • Priority Areas
    • Canada’s Immuno-Engineering and Biomanufacturing Hub
    • COVID-19 Clinical Research Coordination Initiative
    • Academy of Translational Medicine
    • Edwin S.H. Leong Centre for Healthy Aging
    • Centres & Institutes
    • National Prizes
  • Giving
    • Impact of Giving
    • By the Numbers
    • Ways to Give
    • Webinar Series
    • Contact Us
  • Prospective Students
  • Current Learners
    • Policies & Procedures
    • Respectful Environments, Equity, Diversity & Inclusion
    • Mistreatment Help
    • MD & Undergrad Research
    • Summer Student Research Program
    • Multidisciplinary Research Program in Medicine
    • Grad & Postdoc Education
  • Faculty & Staff
  • Clinical Faculty
    • Becoming Clinical Faculty
    • Appointment Policy & Compensation Terms
    • Teaching Tracking & Payment System
    • Services & Perks
    • Career Development
    • Awards
    • Celebrating Clinical Faculty
    • Advisory Council
    • Contacts
  • Alumni
» Home » News » Canada loses out on drug pricing: UBC study

Contact

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421

Canada loses out on drug pricing: UBC study

By Patricia Angel | April 8, 2013

Health systems worldwide are increasingly negotiating secret price rebates from pharmaceutical companies and Canadians risk losing out on the deal.

“The pricing of medicines is now a game of negotiation, similar to buying a car at a dealership,” says Steve Morgan, an Associate Professor in the School of Population and Public Health. “There’s a list price equivalent to a manufacturer’s suggested retail price; and then there’s secret deals that everyone negotiates from there.”

In a study published today in the April issue of the journal Health Affairs, researchers interviewed policymakers from nine developed countries and analyzed practices for securing confidential manufacturers’ rebates.

They confirmed that almost all countries are now routinely negotiating rebates from drug companies as a condition of coverage under their health care systems. Manufacturers are promoting these rebates because the associated confidentiality clause ensures deals struck in one country don’t set precedent in others.

Countries with multi-payer health care systems, including the U.S. and Canada, have less bargaining power in these negotiations. Meanwhile, despite its relatively small population, New Zealand leverages its universal public drug plan to negotiate rebates for all covered medicines.

After “Obama Care” expands health insurance to all Americans in 2014, Canada may be the country least capable of effectively managing this new pricing regime, says Dr. Morgan, an expert in health policy at UBC.

Canada is the only country in the world with universal coverage for medical and hospital care but not for prescription drugs. Individual provinces and insurers negotiate drug prices independently – although some provinces are working cooperatively to lower prices.

“The Canadian system is fundamentally flawed,” says Dr. Morgan. “Ironically, the smaller provinces and uninsured Canadians will end up paying the highest out-of-pocket costs for their medicines.”

About the study

Researchers conducted interviews with pharmaceutical policy makers from Australia, Austria, Canada, Germany, Italy, the Netherlands, New Zealand, the United Kingdom, and the United States. Among these countries, Canada has the second highest level of spending on medicines and the second highest prices for top-selling drugs, behind the United States.

The researchers then held a face-to-face meeting with policy makers from all the participating countries to discuss lessons learned and to refine recommendations regarding best practices. Based on these discussions, Dr. Morgan and his colleagues suggest that policy makers follow three principles in developing a new pricing strategy: pragmatism, discipline and transparency.

Pragmatism: Most countries that have tried performance-based rebate schemes found them difficult to enforce. Governments should strive to keep pharmaceutical rebates relatively simple.

Discipline: Well-designed decision-making systems are required to ensure that drug plans don’t lose control in negotiations with manufacturers.

Transparency: Process transparency is essential because the negotiated price will always remain secret under the new pricing paradigm. Currently, most provinces negotiate rebates from drug manufacturers but few disclose information about the existence, nature, or scale of those rebates.

Contact Information

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421
Faculty of Medicine
317 - 2194 Health Sciences Mall
Vancouver, BC Canada V6T 1Z3
Tel 604 822 2421
Website www.med.ubc.ca
Find us on
    
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility